[BMRN] BioMarin Pharmaceutical Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 85.66 Change: 2.12 (2.54%)
Ext. hours: Change: 0 (0%)

chart BMRN

Refresh chart

Strongest Trends Summary For BMRN

BMRN is in the medium-term down -10% in 2 months and down -16% below S&P in 4 months and down -27% below S&P in 8 months. In the long-term down -23% in 1 year and up 867% in 24 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph

Fundamental Ratios
Shares Outstanding EPS-1.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.98% Sales Growth - Q/Q-11.95% P/E-86.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-4.46% ROE-6.74% ROI-5.17%
Current Ratio4.98 Quick Ratio4.25 Long Term Debt/Equity0.54 Debt Ratio0.13
Gross Margin82.59% Operating Margin-16.48% Net Profit Margin-20.35% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities914.79 M Cash From Investing Activities-750.87 M Cash From Operating Activities-137.81 M Gross Profit170.45 M
Net Profit-67.5 M Operating Profit-66.02 M Total Assets3.66 B Total Current Assets1.52 B
Total Current Liabilities305.51 M Total Debt655.49 M Total Liabilities1.23 B Total Revenue203.26 M
Technical Data
High 52 week106.07 Low 52 week76.01 Last close76.99 Last change0.13%
RSI33.73 Average true range2.22 Beta1.08 Volume685.95 K
Simple moving average 20 days-3.78% Simple moving average 50 days-6.13% Simple moving average 200 days-13.32%
Performance Data
Performance Week-1.09% Performance Month-6.93% Performance Quart-6.6% Performance Half-18.34%
Performance Year-25.48% Performance Year-to-date-9.58% Volatility daily1.48% Volatility weekly3.31%
Volatility monthly6.78% Volatility yearly23.47% Relative Volume211.9% Average Volume1.29 M
New High New Low


2019-09-15 15:28:47 | Stocks That Fell to 3-Year Lows in the Week of Sept. 13

2019-09-13 08:12:56 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Overpaying Its CEO?

2019-09-09 16:05:00 | BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

2019-08-31 09:31:01 | BioMarin BMRN Down 7.3% Since Last Earnings Report: Can It Rebound?

2019-08-28 08:30:00 | BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

2019-08-14 12:06:57 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Trading At A 31% Discount?

2019-08-13 07:00:00 | The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook

2019-08-08 16:29:20 | 6 Underperforming Stocks in Gurus' Portfolios

2019-08-08 10:33:02 | Sarepta SRPT Q2 Loss Widens Y/Y, Golodirsen Nears Approval

2019-08-06 10:45:00 | BioMarin's Roller Coaster Continues

2019-08-03 08:54:04 | Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT

2019-08-02 11:23:36 | Biomarin Pharmaceutical Inc BMRN Q2 2019 Earnings Call Transcript

2019-08-02 10:52:02 | BioMarin BMRN Shares Down on Q1 Earnings & Sales Miss

2019-08-02 09:15:00 | BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried

2019-08-01 18:05:10 | BioMarin Pharmaceutical BMRN Lags Q2 Earnings and Revenue Estimates

2019-08-01 16:05:00 | BioMarin Announces Second Quarter 2019 Financial Results

2019-07-31 09:15:01 | Rate Cut Wait Almost Over

2019-07-29 09:08:01 | What's in the Cards for Sarepta SRPT This Earnings Season?

2019-07-25 10:34:02 | BioMarin Pharmaceutical BMRN Reports Next Week: Wall Street Expects Earnings Growth

2019-07-16 10:16:59 | Health Care Digest: Why 2020 could be big for women's health, Trump's kidney order — and more

2019-07-16 08:30:00 | BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET

2019-07-16 08:03:12 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-07-12 14:25:00 | Shake-Up in Big Weed

2019-07-10 05:57:58 | BioMarin Pharmaceutical Inc.'s NASDAQ:BMRN Shift From Loss To Profit

2019-07-10 05:43:59 | JP Morgan: 2 Gene Therapy Stocks to Buy Now

2019-07-09 10:40:02 | BioMarin BMRN to File for Hemophilia A Candidate in Q4

2019-07-09 08:31:00 | BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors

2019-07-09 08:02:20 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-07-09 06:00:00 | 3 Top Biotech Stocks to Buy in July

2019-07-08 16:18:09 | Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals

2019-07-08 12:58:00 | Here's Why Sangamo Therapeutics Is Surging Today

2019-07-08 09:55:01 | Sarepta Stock Up Almost 40% This Year So Far: Here's Why

2019-07-08 08:01:00 | BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe

2019-07-08 07:30:00 | Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others

2019-07-03 12:03:54 | Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?

2019-07-01 06:00:00 | Healthcare: Drugmakers and Providers Look Attractive

2019-06-26 08:31:00 | BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis ISTH 2019 Congress in Melbourne, Australia from July 6-10, 2019

2019-06-25 09:33:38 | Despite Recent Volatility, Biotech Stocks Look Poised to Pop

2019-06-24 11:04:03 | BioMarin Gets $15M From Pfizer on Talzenna's European Nod

2019-06-24 08:33:12 | Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

2019-06-21 11:30:00 | BioMarin Earns Milestone Payments from Pfizer for TALZENNA® talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

2019-06-17 13:52:12 | Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

2019-06-13 21:08:21 | Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

2019-06-12 07:30:00 | 9 major Bay Area tech employers pay a typical worker more than $200K per year

2019-06-11 16:40:47 | 'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases

2019-06-11 10:24:02 | Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. BMRN

2019-06-10 09:03:39 | Should BioMarin Pharmaceutical NASDAQ:BMRN Be Disappointed With Their 32% Profit?

2019-06-10 08:04:04 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-06-09 12:09:00 | 3 Top Growth Stocks to Buy in June

2019-06-06 10:33:02 | BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady